Accropeutics Unveils Positive Phase 2 Trial Results for AC-201 in Psoriasis Treatment Accropeutics has announced promising Phase 2 trial results for AC-201, an oral TYK2/JAK1 inhibitor, aimed at treating plaque psoriasis, paving the way for further development.

Accropeutics Unveils Positive Phase 2 Trial Results for AC-201 in Psoriasis Treatment #China #Suzhou #Accropeutics #Plaque_Psoriasis #AC-201

Accropeutics Secures $12 Million in Series B Plus Financing to Advance Revolutionary Biotech Treatments Accropeutics Inc. has successfully closed a $12 million Series B Plus financing round to enhance their clinical trials, focusing on immune-mediated diseases.

Accropeutics Secures $12 Million in Series B Plus Financing to Advance Revolutionary Biotech Treatments #United_States #New_York #biotech #Series_B #Accropeutics

Accropeutics Advances with First Patient Dosed in Phase Ib Trial for Innovative Ulcerative Colitis Treatment Accropeutics Inc. has announced the dosing of the first patient in its Phase Ib clinical trial for AC-101, aimed at treating moderate to severe Ulcerative Colitis.

Accropeutics Advances with First Patient Dosed in Phase Ib Trial for Innovative Ulcerative Colitis Treatment #USA #New_York #Ulcerative_Colitis #Accropeutics #AC-101